Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis

Medicine (United States)

Volumn 98, Issue 27, 2019, Pages

  Liang, Ding ^a   Longgui, Ning ^a   Guoqiang, Xu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Intestinal microbiota; Irritable bowel syndrome; Network meta analysis; Probiotics; RCTs

Indexed keywords

PROBIOTIC AGENT;

BIFIDOBACTERIUM; DRUG EFFECT; HUMAN; IRRITABLE COLON; LACTOBACILLUS; META ANALYSIS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIFIDOBACTERIUM; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS; NETWORK META-ANALYSIS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85069269081     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000016068     Document Type: Review

References (46)

1. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Prime 2016;2:16014.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712.e4-21.e4.
3. Nellesen D, Yee K, Chawla A, et al. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm 2013;19:755-64.
4. Wu JC. Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? Gastroenterol Hepatol (N Y) 2010;6:705-11.
5. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-7.
6. Mangell P, Nejdfors P, Wang M, et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci 2002;47:511-6.
7. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
8. Quigley EMM. The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). J Clin Med 2018;7:
9. Quigley EM. Microflora modulation of motility. J Neurogastroenterol Motil 2011;17:140-7.
10. Butel MJ. Probiotics, gut microbiota and health. Med Mal Infect 2014;44:1-8.
11. Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebocontrolled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep 2019;9:5688.
12. Song KH, Jung HK, Kim HJ, et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil 2018;24:197-215.
13. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262-79.
14. Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther 2018;47:1054-70.
15. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2016;150: 1469-1480.e1461.
16. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90.
17. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130: 1538-51.
18. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook. org.
19. Valkenhoef GV, Kuiper J. gemtc: Network Meta-Analysis Using Bayesian Methods. 2016;John Wiley & Sons, Ltd
20. Jafari E, Vahedi H, Merat S, et al. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med 2014;17:466-70.
21. Ki Cha B, Mun Jung S, Hwan Choi C, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrheadominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-7.
22. Ko SJ, Han G, Kim SK, et al. Effect of korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013;2013:824605.
23. Yoon J, Sohn W, Lee O, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014;29:52-9.
24. Yoon H, Park YS, Lee DH, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebocontrolled trial. J Clin Biochem Nutr 2015;57:129-34.
25. Begtrup L, Muckadell O, Kjeldsen J, et al. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127-35.
26. Simren M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:218-27.
27. Sondergaard B, Olsson J, Ohlson K, et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011;46:663-72.
28. Lorenzo-Zuniga V, Llop E, Suarez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014;20:8709-16.
29. Lyra A, Hillila M, Huttunen T, et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 2016;22:10631-42.
30. Pinto-Sanchez M, Hall G, Ghajar K, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 2017;153: 448-459.e448.
31. Roberts LM, McCahon D, Holder R, et al. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013;13:45.
32. Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;33:1123-32.
33. Whelan K. The importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 2014;109:1563-5.
34. Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, et al. A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther 2018;35:289-310.
35. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr 2011;50:1-7.
36. Bogovic Matijasic B, Obermajer T, Lipoglavsek L, et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: a randomized double-blind, placebo-controlled trial. J Dairy Sci 2016;99:5008-21.
37. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014;26:705-14.
38. Hod K, Dekel R, Aviv Cohen N, et al. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2018;30:e13456.
39. Liu HN, Wu H, Chen YZ, et al. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis 2017;49:331-7.
40. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 2017;66:1517-27.
41. Kiefer C, Sturtz S, Bender R. Indirect comparisons and network metaanalyses. Dtsch Arztebl Int 2015;112:803-8.
42. Maukonen J, Satokari R, Matto J, et al. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006;55(pt 5):625-33.
43. West NP, Pyne DB, Cripps AW, et al. Gut Balance, a synbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individuals. Gut Microbes 2012;3:221-7.
44. Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016;16:62.
45. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-61. quiz 1546, 1562.
46. Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:879-81.